ArticleAnalytical and bioanalytical chemistry2025
High-gradient microstructured hybrid microfluidic chip for rare tumor cell capture.
Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An inertial-acoustofluidic platform for bioanalysis: concurrent, high-precision, high-throughput separation of cells and bacteria.Analytical and bioanalytical chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cancer remains the leading cause of death worldwide, and early detection can significantly reduce patient mortality. Circulating tumor cells (CTCs), which are tumor cells shed from the primary tumor and transported to distant sites through the bloodstream, are key biomarkers for cancer diagnosis and contain critical information reflecting the primary tumor, making them important for monitoring cancer progression. Microfluidic chips utilizing a purely physical capture technique based on the size and deformability differences between CTCs and other blood cells have proven to be effective in capturing CTCs. This study investigates three high-gradient microstructured hybrid microfluidic chips (HGMH-Chips), each incorporating a microarray structure and a distinct geometric gradient design: linear, sawtooth, and waveform. Multiphysics simulations revealed significant differences in pressure distribution among the chip configurations. Notably, the sawtooth design exhibited a more uniform pressure drop, with only 25% of the particles in the high-pressure region. We employed two cancer cell lines (MDA-MB-231 and A549) to evaluate the chip's capture capability. Additionally, we compared the capture efficiency and cell viability across the three designs in a single cancer cell system. Experimental results demonstrated that the sawtooth chip achieved a capture efficiency of up to 70%. When applied to mixed samples containing leukocytes, the high-gradient design exhibited a capture purity of up to 98%, effectively isolating a small number of cancer cells from complex samples. This model holds promise for the capture of CTCs in complex systems. Furthermore, the microarray structure aids in stabilizing the captured cancer cells, enhancing separation efficiency. This study presents a novel chip structure design for tumor cell capture, which holds promise for improving the capture of tumor cells in complex biological samples.
Indexed as
Identifiers
40085212What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.